The Latest Breaking News from Alzheimer Disease

Though Alzheimer’s disease affects more than 55 million people worldwide, there’s still no cure for the condition – and treatment options are limited.

One in nine Americans ages 65 and over had Alzheimer’s disease in 2022, and countless others were indirectly affected as caregivers, health care providers and taxpayers. There is currently no cure – available treatments primarily focus on prevention by encouraging protective factors, such as exercise and healthy diet, and reducing…

Research suggests hormone replacement therapy may reduce risk of Alzheimer’s in some women

The U.S. Food and Drug Administration approved the medication lecanemab, sold under the brand name Leqembi, on Jan. 6, 2023, through an “accelerated approval pathway” that fast-tracks promising clinical treatments for diseases in which there are no other currently effective options.

The Food and Drug Administration granted accelerated approval of a disease-modifying treatment that could potentially give some patients with Alzheimer's disease something they haven't had before: a medication that may slow the decline of memory and thinking.

A team of neuroscientists led by a University of Pittsburgh School of Medicine researcher developed a blood test to detect a new marker of Alzheimer's disease neurodegeneration. Read on for details:

‘A blood test is cheaper, safer and easier to administer, and it can improve clinical confidence in diagnosing Alzheimer’s’

The medical profession has never before investigated the effects of traumatic brain injury (TBI), post-traumatic stress disorder (PTSD) and genetic risk factors in a sizable cohort. Read on for details:

Researchers in Scotland have found dolphins with classic markers of Alzheimer's disease in their brains, potentially pointing to the reason the animals became stranded.

On Nov. 30, Eisai and Biogen announced the results of their latest phase 3 clinical trial in Alzheimer’s disease. The verdict: an 18-month treatment with lecanemab slows functional and cognitive loss by 27 per cent in people with mild cognitive impairment or mild dementia due to Alzheimer’s disease. The study…

Bottlenose dolphin, a long-finned pilot whale and a third species found to have markers of the degenerative disease